Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma.

Blood (2012) 120 (21): 2680.

https://doi.org/10.1182/blood.V120.21.2680.2680

Published: 2012

Journal Articles

Immunophenotypic Characteristics of CD34+ Cells According to Genetic Markers in Acute Myeloid Leukemias with Normal Karyotype.

Mauricio A Chandía, MD, Ma Belén Vidriales, MD, PhD, Carmen Chillón, PhD, Marcos González, MD, PhD, Norma Gutiérrez, MD, PhD, Jesús F San Miguel, MD, PhD

Blood (2012) 120 (21): 2554.

https://doi.org/10.1182/blood.V120.21.2554.2554

Published: 2012

Journal Articles

Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14.

Ana E Rodríguez, Jose Ángel Hernández-Rivas, Alberto Risueño, Encarna Fermiñán, Natalia de las Heras, Alfonso Garcia de Coca, Carlos Aguilar, Juan Nicolás Rodríguez, Josefina Galende, Javier de las Rivas, Jesús F San Miguel, MD, Marcos González, Jesús M Hernández-Rivas

Blood (2012) 120 (21): 2871.

https://doi.org/10.1182/blood.V120.21.2871.2871

Published: 2012

Journal Articles

Assessment of Minimal Residual Disease Levels in B-CLL After Front-Line Treatment with FC-R and Rituximab Maintenance

Blood (2012) 120 (21): 4599.

https://doi.org/10.1182/blood.V120.21.4599.4599

Published: 2012

Journal Articles

6q Deletion Helps in the Discrimination Between Symptomatic Waldenström's Macroglobulinemia and Asymptomatic Forms of IgM Monoclonal Gammopathies

Ramón García-Sanz, Roberto JP Magalhaes, Enrique M Ocio, MD, PhD, Pilar Giraldo, MD, PhD, Natalia de las Heras, Carmen Aguilera, Jose Mariano Hernández, Alfonso Garcia de Coca, Noemi Puig, Ilda Murillo, MD, Elena Sebastian, MD, Marcos González, Jesus F. San Miguel, MD, PhD, Norma Gutierrez

Blood (2012) 120 (21): 4566.

https://doi.org/10.1182/blood.V120.21.4566.4566

Published: 2012

Journal Articles

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Pau Abrisqueta, MD, Neus Villamor, MD, PhD, María José Terol, MD, PhD, Eva González-Barca, MD, PhD, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose Antonio García-Marco, MD, PhD, Yolanda González, MD, Felix Carbonell, MD, PhD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, MD, Ana Muntanola, MD, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD, Francesc Bosch, MD, PhD

Blood (2012) 120 (21): 3930.

https://doi.org/10.1182/blood.V120.21.3930.3930

Published: 2012

Journal Articles

Age, Performance Status and Plasma Interleukin-10 Levels At Diagnosis: A Triad for Improving Survival Prediction of Patients with Myelodysplastic Syndromes Already Stratified by IPSS-R. Spanish MDS Group (GESMD)

Fernando Ramos, MD, PhD, MPH, Carmen Pedro, Jose-Maria Garcia-Ruiz-de-Morales, Eva Barragan, Raquel de Paz, Andres Insunza, Mar Tormo, Maria Diez-Campelo, Blanca Xicoy, Eduardo Salido, Javier Sanchez-del-Real, Leonor Arenillas, Carlos Santamaria, Noemi Puig, Lourdes Florensa, Francesc Sole, Marcos González, Elisa Luño, Guillermo F Sanz

Blood (2012) 120 (21): 3803.

https://doi.org/10.1182/blood.V120.21.3803.3803

Published: 2012

Journal Articles

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Andrew Grigg, MBBS, FRACP, FRCPA, Marcos González, Martin Dreyling, Simon A. Rule, MD, Guiyuan Lei, Elisabeth Wassner-Fritsch, Michael K. Wenger, MD, Paula Marlton, MBBS, FRACP, FRCPA

Blood (2012) 120 (21): 3686.

https://doi.org/10.1182/blood.V120.21.3686.3686

Published: 2012

Journal Articles

Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma

Miguel Alcoceba, Elena Sebastián, Ana Balanzategui, Luis Marín, Santiago Montes-Moreno, Teresa Flores, Noemí Puig, M. Eugenia Sarasquete, M. Carmen Chillón, Cristina Jiménez, Rocío Corral, Eva González-Barca, M. Dolores Caballero, Jesús F. San Miguel, Ramón García-Sanz, Marcos González

Blood (2012) 120 (21): 1589.

https://doi.org/10.1182/blood.V120.21.1589.1589

Published: 2012

Journal Articles

Different Clinical Features but Not Outcome in SLL Patients Compared to CLL,

Alejandra Martinez-Trillos, MD, Eva Gine, MD, Jordina Rovira, MD, Marcos González, MD, Maria Jose Terol, MD, Julio Delgado, MD, Maria Rozman, MD, PhD, Martha Aymerich, MD, Elias Campo, MD, Armando Lopez-Guillermo, MD, Neus Villamor, MD. PhD

Blood (2011) 118 (21): 3896.

https://doi.org/10.1182/blood.V118.21.3896.3896

Published: 2011

Journal Articles

Lenalidomide Differentially Modifies the Genomic Profile and miRNA Expression of Mesenchymal Stromal Cells From Patients with 5q- Syndrome,

Sandra Muntión, PhD, Carlos Santamaría, PhD, Beatriz Roson, Carlos Romo, Olga López-Villar, MD, PhD, Soraya Carrancio, PhD, Fermin M. Sanchez-Guijo, MD, PhD, María Diez-Campelo, MD, PhD, Maria-Eugenia Sarasquete, PhD, Javier de las Rivas, PhD, Marcos González, MD, Jesus F. San Miguel, MD, PhD, Maria-Consuelo del Cañizo, MD, PhD

Blood (2011) 118 (21): 3810.

https://doi.org/10.1182/blood.V118.21.3810.3810

Published: 2011

Journal Articles

The Genotype in the Donor and Recipient for the Polymorphim −174 G/C of the IL-6 Influences the Outcome of HLA-Identical Related Stem Cell Transplantation,

Blood (2011) 118 (21): 4082.

https://doi.org/10.1182/blood.V118.21.4082.4082

Published: 2011

Journal Articles

SNP-Based Mapping Arrays Reveal High Genomic Complexity in Monoclonal Gammopathies: From the MGUS to Myeloma Status

Lucía López-Corral, Maria Eugenia Sarasquete, Sílvia Beà, Ramón García-Sanz, Maria Victoria Mateos, Marcos González, MD, Luis Antonio Corchete, Joan Bladé, MD, Albert Oriol-Rocafiguera, Miguel Hernandez, Pilar Giraldo, Jose Hernández, Jesús M Hernández-Rivas, Jesús F San Miguel, Norma C. Gutierrez

Blood (2011) 118 (21): 295.

https://doi.org/10.1182/blood.V118.21.295.295

Published: 2011

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Francesc Bosch, MD, PhD, Pau Abrisqueta, Neus Villamor, MD. PhD, María José Terol, MD, PhD, Eva González-Barca, MD, Marcos González, MD, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD

Blood (2011) 118 (21): 293.

https://doi.org/10.1182/blood.V118.21.293.293

Published: 2011

Journal Articles

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Blood (2010) 116 (21): 2448.

https://doi.org/10.1182/blood.V116.21.2448.2448

Published: 2010

Journal Articles

Mesenchymal Stromal Cells From Myelodysplastic Syndrome Patients Show Lower DICER1 and DROSHA Expression, as Well as Decreased Mir-155 and Mir-181a MicroRNA Expression, When Compared with Healthy Controls

Carlos Santamaría, Olga López-VIllar, Sandra Muntión, Belén Blanco, Soraya Carrancio, Fermin M. Sanchez-Guijo, María Diez-Campelo, Stela Álvarez-Fernández, María E. Sarasquete, Marcos González, Jesús F. San Miguel, María C. Del Cañizo

Blood (2010) 116 (21): 397.

https://doi.org/10.1182/blood.V116.21.397.397

Published: 2010

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Francesc Bosch, MD, PhD, Neus Villamor, Pau Abrisqueta, MD, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, MD, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD

Blood (2010) 116 (21): 1382.

https://doi.org/10.1182/blood.V116.21.1382.1382

Published: 2010

Journal Articles

Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.

Francisco Cervantes, Pilar López-Garrido, María-Isabel Montero, Fermín Jonte, Jesus Martinez, Juan-Carlos Hernández-Boluda, MD, PhD, María Calbacho, Anna Sureda, MD, PhD, Gloria Pérez-Rus, José Nieto, MD, Cristina Pérez-López, José Román, Marcos González, Arturo Pereira, Dolors Colomer

Blood (2009) 114 (22): 1113.

https://doi.org/10.1182/blood.V114.22.1113.1113

Published: 2009

Journal Articles

Screening Thousands of Drugs in Leukemia Patient Samples to Identify Novel Uses for Approved Drugs.

Blood (2009) 114 (22): 4414.

https://doi.org/10.1182/blood.V114.22.4414.4414

Published: 2009

Journal Articles

A High Number of Losses in 13q14 Chromosome Is Associated with a Worse Outcome and Biological Differences in Patients with B Chronic Lymphoid Leukemia.

José-Ángel Hernández, Ana-Eugenia Rodríguez, Marcos González, Rocío Benito, Celia Fontanillo, Virgilio Sandoval, Mercedes Romero, Guillermo Martín-Núñez, Alfonso García de Coca, Rosa Fisac, Josefina Galende, Isabel Recio, Francisco Ortuño, Juan-Luis García, Javier de las Rivas, Norma-Carmen Gutiérrez, Jesús-Maria Hernández, J.F. San Miguel

Blood (2008) 112 (11): 2073.

https://doi.org/10.1182/blood.V112.11.2073.2073

Published: 2008

NARROW

Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma.

Immunophenotypic Characteristics of CD34+ Cells According to Genetic Markers in Acute Myeloid Leukemias with Normal Karyotype.

Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14.

Assessment of Minimal Residual Disease Levels in B-CLL After Front-Line Treatment with FC-R and Rituximab Maintenance

6q Deletion Helps in the Discrimination Between Symptomatic Waldenström's Macroglobulinemia and Asymptomatic Forms of IgM Monoclonal Gammopathies

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Age, Performance Status and Plasma Interleukin-10 Levels At Diagnosis: A Triad for Improving Survival Prediction of Patients with Myelodysplastic Syndromes Already Stratified by IPSS-R. Spanish MDS Group (GESMD)

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma

Different Clinical Features but Not Outcome in SLL Patients Compared to CLL,

Lenalidomide Differentially Modifies the Genomic Profile and miRNA Expression of Mesenchymal Stromal Cells From Patients with 5q- Syndrome,

The Genotype in the Donor and Recipient for the Polymorphim −174 G/C of the IL-6 Influences the Outcome of HLA-Identical Related Stem Cell Transplantation,

SNP-Based Mapping Arrays Reveal High Genomic Complexity in Monoclonal Gammopathies: From the MGUS to Myeloma Status

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Mesenchymal Stromal Cells From Myelodysplastic Syndrome Patients Show Lower DICER1 and DROSHA Expression, as Well as Decreased Mir-155 and Mir-181a MicroRNA Expression, When Compared with Healthy Controls

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.

Screening Thousands of Drugs in Leukemia Patient Samples to Identify Novel Uses for Approved Drugs.

A High Number of Losses in 13q14 Chromosome Is Associated with a Worse Outcome and Biological Differences in Patients with B Chronic Lymphoid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only